[Skip to Navigation]
Sign In
Comment & Response
April 14, 2022

Clinical Utility Assessment of Gonadotropin-Releasing Hormone Analogs Among Women Younger Than 35 Years

Author Affiliations
  • 1Insitro, South San Francisco, California
  • 2Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts
JAMA Oncol. 2022;8(6):943-944. doi:10.1001/jamaoncol.2022.0488

To the Editor In their randomized clinical trial reported recently in JAMA Oncology, Zong and colleagues1 examined the efficacy of gonadotropin-releasing hormone analog (GnRHa) treatment administered during chemotherapy for reducing premature ovarian insufficiency among women with breast cancer. Key secondary analyses included overall survival (OS) and tumor-free survival (TFS) among patients younger than 35 years. In particular, 4-year OS and TFS were significantly improved with GnRHa treatment (OS, 100% vs 81%; P = .01; TFS, 93% vs 62%; P = .004). However, this cross-sectional analysis does not take the time to event into consideration. Results from hazard ratio (HR) analysis, which does consider the time to event, were also reported. These supported a difference in the case of TFS (HR, 0.15; P = .03), but not in that of OS (HR, 0.02; P = .37).

Add or change institution